Morgan Stanley maintains RenaissanceRe Holdings at Equal-Weight, raises price target to $365 from $335
Morgan Stanley kept RenaissanceRe Holdings at Equal-Weight, raising its price target to $365 from $335, a 9.0% increase. The new target implies a 2.4% upside from the Nov 16 close of $356.59. Recent analyst price targets for the company range from $338 to $385.
How this was made

The 30-second read
Why it matters
The only actionable content is the price-target increase, which can influence near-term sentiment but does not introduce new operational or financial information from the company.
Market read
A modest bullish analyst PT revision for RNR, with limited upside implied from the referenced close and no new company catalyst.
What to watch
Traders may already have priced prior analyst targets (range $338 to $385 over 30 days), reducing incremental impact from this specific PT update.
Background
The article summarizes a Morgan Stanley analyst action on RenaissanceRe Holdings, including a maintained rating and a raised price target.
Ticker impact
Morgan Stanley maintained RenaissanceRe at Equal-Weight and raised its price target to $365 from $335, implying modest upside from the Nov 16 close.
Likely mild upward bias as traders price in the higher target, though magnitude should be limited without fresh earnings or guidance.
This is an analyst note update (PT change) rather than a new disclosure from RenaissanceRe; the stated upside is small and the article lacks a new catalyst.
Market effects
Limited read-through to reinsurance peers since this is a single-name analyst target change without sector-wide new information.
No direct regional market catalyst described.
No global macro or cross-market linkage beyond general sentiment.
Counterpoint
The small implied upside and lack of new company-specific news suggest the PT change may not meaningfully move the stock versus broader market drivers.
Key entities
- companyRenaissanceRe Holdings
Subject of the analyst note, rated Equal-Weight with a raised price target to $365.
- analyst_firmMorgan Stanley
Maintained the rating and increased the price target.


